Prothena to Present at the 2015 Credit Suisse Healthcare Conference on November 10
04 nov. 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Nov. 04, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Reports Third Quarter 2015 Financial Results and Provides R&D Update
02 nov. 2015 16h05 HE
|
Prothena Corporation plc
Net cash used in operating activities was $16.9 million in the third quarter and $42.8 million for first nine months of 2015; quarter-end cash position of $387.8 million provides solid runway for...
Prothena to Initiate PRONTO, a Global Trial of NEOD001 in Patients With AL Amyloidosis With Primary Endpoint of Cardiac Response
15 oct. 2015 16h05 HE
|
Prothena Corporation plc
Accelerates Development Timeline and Potential Path to PatientsProthena to Host Investor Conference Call and Webcast Today at 4:30 p.m. ET DUBLIN, Ireland, Oct. 15, 2015 (GLOBE NEWSWIRE) -- ...
Prothena to Present at Ladenburg Thalmann 2015 Healthcare Conference on September 29
22 sept. 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Reports Second Quarter 2015 Financial Results and Provides R&D Update
04 août 2015 16h05 HE
|
Prothena Corporation plc
Net cash used in operating activities was $11.1 million in the second quarter and $25.9 million for first six months of 2015; completion of successful public equity offering netting $131.4...
Prothena Announces Addition of Seasoned Executive to Board of Directors
29 juin 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 29, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease
17 juin 2015 07h00 HE
|
Prothena Corporation plc
PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
Dose- and Time-Dependent, Statistically Significant Reduction in Free Serum Alpha-Synuclein within One...
Prothena to Present at JMP Securities Life Science Conference 2015 on June 23
16 juin 2015 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 16, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena's NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association
12 juin 2015 07h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 12, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association
12 juin 2015 07h00 HE
|
Prothena Corporation plc
72% of Survey Respondents had AL Amyloidosis
54% of Patients with AL Amyloidosis Reported Difficulty Tolerating Current Off-Label Treatments
Diagnosis of AL Amyloidosis is Often Missed by...